{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T22:31:01Z","timestamp":1775082661776,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.vascn.2024.107515","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T16:18:47Z","timestamp":1716221927000},"page":"107515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Improving the in vivo QTc assay: Nonclinical concentration-QTc modeling for risk assessment"],"prefix":"10.1016","volume":"128","author":[{"given":"Todd A.","family":"Wisialowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Ether","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Michael","family":"Foley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Kleiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yevgeniya","family":"Koshman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Leishman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Martel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill V.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Popp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sridharan","family":"Rajamani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Riley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric I.","family":"Rossman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo M.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vascn.2024.107515_bb0005","series-title":"ICH E14\/S7B Implementation Working Group: Clinical and Nonclinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential Questions and Answers","author":"Anonymous","year":"2022"},{"key":"10.1016\/j.vascn.2024.107515_bb0010","article-title":"ICH E14\/S7B implementation working group: E14\/S7B questions and answers: Clinical and nonclinical evaluation of QT\/QTc interval prolongation and Proarrhythmic potential","author":"Anonymous","year":"2022","journal-title":"Training Materials."},{"issue":"6","key":"10.1016\/j.vascn.2024.107515_bb0015","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1111\/cts.13103","article-title":"Evaluation of moxifloxacin in canine and non-human primate telemetry assays: Comparison of QTc interval prolongation by timepoint and concentration-QTc analysis","volume":"14","author":"Chui","year":"2021","journal-title":"Clinical and Translational Science"},{"issue":"4","key":"10.1016\/j.vascn.2024.107515_bb0020","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/cpt.60","article-title":"Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase","volume":"97","author":"Darpo","year":"2015","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"1","key":"10.1016\/j.vascn.2024.107515_bb0025","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/anec.12128","article-title":"The IQ-CSRC prospective clinical phase 1 study: \u201ccan early QT assessment using exposure response analysis replace the thorough QT study?\u201d","volume":"19","author":"Darpo","year":"2014","journal-title":"Annals of Noninvasive Electrocardiology"},{"issue":"3","key":"10.1016\/j.vascn.2024.107515_bb0030","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/cts.13454","article-title":"Evaluation of levocetirizine in beagle dog and cynomolgus monkey telemetry assays: Defining the no QTc effect profile by timepoint and concentration-QTc analysis","volume":"16","author":"Engwall","year":"2023","journal-title":"Clinical and Translational Science"},{"key":"10.1016\/j.vascn.2024.107515_bb0035","doi-asserted-by":"crossref","first-page":"107247","DOI":"10.1016\/j.vascn.2022.107247","article-title":"Reference intervals and method sensitivity for electrocardiology, hemodynamics, and body temperature parameters in healthy cynomolgus monkeys","volume":"120","author":"Fang","year":"2023","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"8","key":"10.1016\/j.vascn.2024.107515_bb0040","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1177\/0091270010381498","article-title":"Population pharmacokinetic and concentration\u2013QTc models for moxifloxacin: Pooled analysis of 20 thorough QT studies","volume":"51","author":"Florian","year":"2011","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.vascn.2024.107515_bb0045","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10928-017-9558-5","article-title":"Scientific white paper on concentration-QTc modeling","volume":"45","author":"Garnett","year":"2018","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"key":"10.1016\/j.vascn.2024.107515_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vascn.2014.12.008","article-title":"Sensitivity of pharmacokinetic-pharmacodynamic analysis for detecting small magnitudes of QTc prolongation in preclinical safety testing","volume":"72","author":"Gotta","year":"2015","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2024.107515_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2019.106606","article-title":"Japan activity for improvement of cardiovascular evaluation by telemetry system (J-ICET). Exposure-response analysis of drug-induced QT interval prolongation in telemetered monkeys for translational prediction to human","volume":"99","author":"Komatsu","year":"2019","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2024.107515_bb0060","series-title":"SPS 2023 Annual Meeting in Brussels, Belgium. September 18-21","article-title":"Outcomes and learnings of a joined prospective study evaluating the sensitivity of the in vivo dog QT assay in line with the ICH E14\/S7B Q&A best practices","author":"Martel","year":"2023"},{"key":"10.1016\/j.vascn.2024.107515_bib116","first-page":"18","article-title":"Assessment of moxifloxacin-induced QTc prolongation in canine and nonhuman primate using a linear mixed effect modeling approach. Poster Presentation #017 - SPS 2023 Annual Meeting in Brussels, Belgium","author":"Patel","year":"2023","journal-title":"September"},{"key":"10.1016\/j.vascn.2024.107515_bb0080","series-title":"SPS 2023 Annual Meeting in Brussels, Belgium. September 18-21","article-title":"Nonclinical Comprehensive Exposure Response QTc-Modeling (NCERT) in Telemetry Instrumented Conscious Dogs Using Automated Blood Sampling","author":"Koshman","year":"2023"},{"issue":"2","key":"10.1016\/j.vascn.2024.107515_bb0085","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/0192623316663865","article-title":"Assessment of cardiac troponin I responses in nonhuman primates during restraint, blood collection, and dosing in preclinical safety studies","volume":"45","author":"Reagan","year":"2017","journal-title":"Toxicologic Pathology"},{"key":"10.1016\/j.vascn.2024.107515_bb0090","doi-asserted-by":"crossref","first-page":"107270","DOI":"10.1016\/j.vascn.2023.107270","article-title":"Best practice considerations for nonclinical in vivo cardiovascular telemetry studies in non-rodent species: Delivering high quality QTc data to support ICH E14\/S7B Q&as","volume":"123","author":"Rossman","year":"2023","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2024.107515_bb0095","article-title":"Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: A comparison in humans and other mammalian species","volume":"43 Suppl B:69-76","author":"Siefert","year":"1999","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.vascn.2024.107515_bb0100","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.vascn.2010.05.011","article-title":"Cardiovascular safety assessments in the conscious telemetered dog: Utilisation of super-intervals to enhance statistical power","volume":"62","author":"Sivarajah","year":"2010","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"2","key":"10.1016\/j.vascn.2024.107515_bb0105","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/cpt.2137","article-title":"Translational models and tools to reduce clinical trials and improve regulatory decision making for QTc and Proarrhythmia risk (ICH E14\/S7B updates)","volume":"109","author":"Strauss","year":"2021","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"2","key":"10.1016\/j.vascn.2024.107515_bb0110","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cpt.2029","article-title":"Time for a fully integrated nonclinical-clinical risk assessment to streamline QT prolongation liability determinations: A Pharma industry Perspective","volume":"109","author":"Vargas","year":"2021","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"3","key":"10.1016\/j.vascn.2024.107515_bb0115","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.vascn.2011.03.002","article-title":"Pharmacokinetic-pharmacodynamic modelling of the effect of moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys","volume":"63","author":"Watson","year":"2011","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2024.107515_bib117","first-page":"18","article-title":"Implementation of Non-Clinical C-QTc Analysis: Demonstration of Clinically Relevant Detection Sensitivity Consistent With ICH E14\/S7B Q&A and Evidence of Clinical Translation. Poster Presentation #023 - SPS 2023 Annual Meeting in Brussels, Belgium","author":"Wisialowski","year":"2023","journal-title":"September"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105687192400025X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105687192400025X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T22:09:30Z","timestamp":1737756570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105687192400025X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":22,"alternative-id":["S105687192400025X"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2024.107515","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving the in vivo QTc assay: Nonclinical concentration-QTc modeling for risk assessment","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2024.107515","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107515"}}